[go: up one dir, main page]

AR072153A1 - Formas solidas de (1r,2s 3r) -1-(2- (isoxazol-3-il) -1h-imidazol-4-il) butano-1,2,3,4 -tetraol, un metodo para tratar o prevenir una enfermedad y una forma de administracion farmaceutica - Google Patents

Formas solidas de (1r,2s 3r) -1-(2- (isoxazol-3-il) -1h-imidazol-4-il) butano-1,2,3,4 -tetraol, un metodo para tratar o prevenir una enfermedad y una forma de administracion farmaceutica

Info

Publication number
AR072153A1
AR072153A1 ARP090102172A ARP090102172A AR072153A1 AR 072153 A1 AR072153 A1 AR 072153A1 AR P090102172 A ARP090102172 A AR P090102172A AR P090102172 A ARP090102172 A AR P090102172A AR 072153 A1 AR072153 A1 AR 072153A1
Authority
AR
Argentina
Prior art keywords
disease
tetraol
isoxazol
imidazol
butane
Prior art date
Application number
ARP090102172A
Other languages
English (en)
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of AR072153A1 publication Critical patent/AR072153A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se presenta el compuesto cristalino o un hidrato del mismo. Estos compuestos son utiles en el tratamiento de enfermedades tales como asma, dermatitis atopica, enfermedad de injerto versus huesped, miastenia grave, psoriasis, artritis reumatoide, rechazo a transplantes y diabetes.
ARP090102172A 2008-06-18 2009-06-16 Formas solidas de (1r,2s 3r) -1-(2- (isoxazol-3-il) -1h-imidazol-4-il) butano-1,2,3,4 -tetraol, un metodo para tratar o prevenir una enfermedad y una forma de administracion farmaceutica AR072153A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7339808P 2008-06-18 2008-06-18

Publications (1)

Publication Number Publication Date
AR072153A1 true AR072153A1 (es) 2010-08-11

Family

ID=41381634

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102172A AR072153A1 (es) 2008-06-18 2009-06-16 Formas solidas de (1r,2s 3r) -1-(2- (isoxazol-3-il) -1h-imidazol-4-il) butano-1,2,3,4 -tetraol, un metodo para tratar o prevenir una enfermedad y una forma de administracion farmaceutica

Country Status (20)

Country Link
US (1) US7998994B2 (es)
EP (1) EP2315765B1 (es)
JP (1) JP5550644B2 (es)
KR (1) KR20110036582A (es)
CN (1) CN102131803A (es)
AR (1) AR072153A1 (es)
AU (1) AU2009271408A1 (es)
BR (1) BRPI0914167A2 (es)
CA (1) CA2728094A1 (es)
CL (1) CL2009001436A1 (es)
CO (1) CO6341474A2 (es)
DK (1) DK2315765T3 (es)
ES (1) ES2401555T3 (es)
IL (1) IL209815A0 (es)
MX (1) MX2010013991A (es)
PE (1) PE20100085A1 (es)
RU (1) RU2011101535A (es)
TW (1) TW201004943A (es)
UY (1) UY31900A (es)
WO (1) WO2010008733A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201002698A (en) * 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
US8653126B2 (en) 2010-02-18 2014-02-18 Daiichi Sankyo Company, Limited Imidazole derivative
WO2012002274A1 (ja) 2010-06-28 2012-01-05 第一三共株式会社 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法
DE102011103751A1 (de) 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Kristallisierung von Epirubicinhydrochlorid
US9120835B2 (en) 2011-06-28 2015-09-01 Daiichi Sankyo Company Limited Phosphoric acid ester derivatives
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
DE4430289A1 (de) * 1993-09-04 1995-03-09 Basf Ag Verbessertes Verfahren zur Herstellung von Astaxanthin
AU2881797A (en) * 1996-05-31 1998-01-05 University Of Wollongong, The Acetyl derivatives of thiazoles and analogues
JPH1149972A (ja) * 1997-07-31 1999-02-23 Jiyun Internatl:Kk 殻廃棄物からアスタキサンチン及びキトーサンを同時に生成する方法
EP2266419A1 (en) * 2005-05-23 2010-12-29 Phares Drug Delivery AG Direct dissolution of carotenoids in edible oils and fats
CA2612592A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
ITMI20052486A1 (it) * 2005-12-23 2007-06-24 Italiana Sint Spa Procedimento di sintesi di intermedi per la preparazione di astaxantina
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200848029A (en) * 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
TW201002698A (en) 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
EP2346504A1 (en) * 2008-08-22 2011-07-27 Lexicon Pharmaceuticals, Inc. Combinations comprising bicyclic s1p lyase inhibitors

Also Published As

Publication number Publication date
CO6341474A2 (es) 2011-11-21
WO2010008733A2 (en) 2010-01-21
PE20100085A1 (es) 2010-02-05
MX2010013991A (es) 2011-01-14
TW201004943A (en) 2010-02-01
RU2011101535A (ru) 2012-07-27
US7998994B2 (en) 2011-08-16
WO2010008733A3 (en) 2010-03-25
US20090318516A1 (en) 2009-12-24
IL209815A0 (en) 2011-02-28
AU2009271408A1 (en) 2010-01-21
UY31900A (es) 2010-01-29
BRPI0914167A2 (pt) 2015-10-20
CN102131803A (zh) 2011-07-20
JP5550644B2 (ja) 2014-07-16
KR20110036582A (ko) 2011-04-07
DK2315765T3 (da) 2013-03-25
CA2728094A1 (en) 2010-01-21
ES2401555T3 (es) 2013-04-22
EP2315765B1 (en) 2012-12-19
EP2315765A2 (en) 2011-05-04
JP2011524915A (ja) 2011-09-08
CL2009001436A1 (es) 2010-10-01

Similar Documents

Publication Publication Date Title
AR072153A1 (es) Formas solidas de (1r,2s 3r) -1-(2- (isoxazol-3-il) -1h-imidazol-4-il) butano-1,2,3,4 -tetraol, un metodo para tratar o prevenir una enfermedad y una forma de administracion farmaceutica
CL2008000790A1 (es) Compuestos derivados de purina sustituida; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis, artritis, psoriasis y cancer.
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CL2014002541A1 (es) Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades.
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
BR112015023267A2 (pt) composto
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
CY1115455T1 (el) Χρησιμοποιηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια του πονου νευροπαθειας
EA201391568A1 (ru) Новые производные имидазола, подходящие для лечения артрита
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
IL211678A0 (en) Smoothened antagonism for the treatment of hedgehog pathway-related disorders
WO2013033037A3 (en) Novel antiprion compounds
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
CL2008000422A1 (es) El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
CL2014000441A1 (es) Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer.
EP2669382A4 (en) Cellulosic biomass treatment method, method of producing sugar, alcohol or organic acid from cellulosic biomass
MX391127B (es) Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso.
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
MX2014010910A (es) Sales novedosas de trimebutina basadas en sulfonato.
WO2010079045A3 (en) Crystalline salt forms of flibanserine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal